Published in J Virol on January 01, 1992
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog (2006) 3.97
Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci U S A (1993) 3.63
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A (2009) 3.47
Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J (1996) 2.84
Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol (1994) 2.83
Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol (1993) 2.63
CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol (1996) 2.61
The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol (1995) 2.48
HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem (2009) 2.42
CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol (1998) 2.38
Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol (1994) 2.29
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol (1995) 2.22
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology (2009) 2.11
The membrane-proximal intracytoplasmic tyrosine residue of HIV-1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells. EMBO J (1997) 2.10
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export. J Virol (1992) 2.05
Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J Virol (1993) 1.86
Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog (2010) 1.85
Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol (2006) 1.77
Nef from primary isolates of human immunodeficiency virus type 1 suppresses surface CD4 expression in human and mouse T cells. J Virol (1993) 1.77
The ubiquitin system, disease, and drug discovery. BMC Biochem (2008) 1.73
Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog (2010) 1.66
Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J Virol (1993) 1.63
The cytoplasmic domain of CD4 is sufficient for its down-regulation from the cell surface by human immunodeficiency virus type 1 Nef. J Virol (1994) 1.60
Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol (2010) 1.60
The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med (1997) 1.55
Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci (2002) 1.54
The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog (2010) 1.52
Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology (2007) 1.48
Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef. J Virol (1993) 1.48
Molecular biology of the human immunodeficiency virus accessory proteins. J Virol (1994) 1.44
The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors. J Exp Med (2001) 1.38
Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol (2010) 1.37
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
The majority of cells are superinfected in a cloned cell line that produces high levels of human immunodeficiency virus type 1 strain MN. J Virol (1995) 1.34
Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J Virol (1999) 1.31
HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio (2011) 1.30
Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin. J Virol (1993) 1.29
Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Biochem J (1996) 1.27
Sequences present in the cytoplasmic domain of CD4 are necessary and sufficient to confer sensitivity to the human immunodeficiency virus type 1 Vpu protein. J Virol (1994) 1.27
Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology (2010) 1.26
Molecular biology and pathogenesis of animal lentivirus infections. Clin Microbiol Rev (1996) 1.26
BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog (2009) 1.24
Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles. PLoS Pathog (2007) 1.13
HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med (2010) 1.09
β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology (2011) 1.07
Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function. J Virol (1993) 1.07
High level of surface CD4 prevents stable human immunodeficiency virus infection of T-cell transfectants. J Virol (1992) 1.03
Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release. Virology (2008) 1.03
C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif. J Biol Chem (2011) 1.01
Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry. J Virol (2011) 1.01
Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing. J Virol (1999) 0.98
HIV-induced apoptosis requires the CD4 receptor cytoplasmic tail and is accelerated by interaction of CD4 with p56lck. J Exp Med (1996) 0.98
Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression. J Virol (2003) 0.96
Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule. J Virol (1997) 0.95
Negative factor from SIV binds to the catalytic subunit of the V-ATPase to internalize CD4 and to increase viral infectivity. Mol Biol Cell (2001) 0.92
Comparative NMR studies demonstrate profound differences between two viroporins: p7 of HCV and Vpu of HIV-1. Biochim Biophys Acta (2010) 0.92
HIV-1 Vpu - an ion channel in search of a job. Biochim Biophys Acta (2013) 0.91
ERAD and how viruses exploit it. Front Microbiol (2014) 0.91
The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release. J Virol (2011) 0.90
Mechanisms underlying HIV-1 Vpu-mediated viral egress. Front Microbiol (2014) 0.86
Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med (1997) 0.86
Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology (2010) 0.85
Retracted Murine leukemia virus envelope protein in transgenic-mouse serum blocks infection in vitro. J Virol (1996) 0.84
Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu. J Virol (2009) 0.84
Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression. Virology (2009) 0.83
CD4 and BST-2/tetherin proteins retro-translocate from endoplasmic reticulum to cytosol as partially folded and multimeric molecules. J Biol Chem (2013) 0.81
Direct internalization of cell-surface BST-2/tetherin by the HIV-1 accessory protein Vpu. Commun Integr Biol (2010) 0.81
Viral replication is enhanced by an HIV-1 intersubtype recombination-derived Vpu protein. Virol J (2010) 0.80
The role of BST-2/Tetherin in host protection and disease manifestation. Immun Inflamm Dis (2015) 0.79
Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu. J Virol (2011) 0.79
Vpu Protein: The Viroporin Encoded by HIV-1. Viruses (2015) 0.78
Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1. J Virol (1995) 0.78
Delayed human immunodeficiency virus type 1-induced apoptosis in cells expressing truncated forms of CD4. J Virol (1998) 0.78
Novel Acylguanidine-Based Inhibitor of HIV-1. J Virol (2016) 0.78
Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and Persistence. Viruses (2016) 0.77
Human immunodeficiency virus type 2 produces a defect in CD3-gamma gene transcripts similar to that observed for human immunodeficiency virus type 1. J Virol (1999) 0.77
Bacteria-based analysis of HIV-1 Vpu channel activity. PLoS One (2014) 0.76
Viral Membrane Channels: Role and Function in the Virus Life Cycle. Viruses (2015) 0.76
The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes. J Virol (2003) 0.75
Functional conservation and coherence of HIV-1 subtype A Vpu alleles. Sci Rep (2017) 0.75
Functional conservation and coherence of HIV-1 subtype A Vpu alleles. Sci Rep (2017) 0.75
HIV-1 Vpu Downmodulates ICAM-1 Expression, Resulting in Decreased Killing of Infected CD4(+) T Cells by NK Cells. J Virol (2017) 0.75
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A (1982) 20.55
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 6.39
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV. Science (1986) 4.79
Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology (1991) 4.77
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol (1990) 3.42
HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (1990) 3.37
CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J Virol (1990) 2.96
Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO J (1990) 2.93
Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc Natl Acad Sci U S A (1991) 2.54
Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum. Nature (1990) 2.48
Intracellular processing of the gp160 HIV-1 envelope precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex. J Biol Chem (1990) 2.35
Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing. Virology (1991) 2.05
Downregulation of cell surface molecules during noncytopathic infection of T cells with human immunodeficiency virus. J Virol (1987) 1.85
Depletion of the surface CD4 molecule by the envelope protein of human immunodeficiency virus expressed in a human CD4+ monocytoid cell line. J Virol (1989) 1.73
Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport. J Virol (1989) 1.53
HIV-2 link to AIDS in West Africa. J Acquir Immune Defic Syndr (1990) 1.13
Perturbation of host-cell membrane is a primary mechanism of HIV cytopathology. Virology (1991) 1.01
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Quantitation of Simian virus 40 sequences in African green monkey, mouse and virus-transformed cell genomes. J Mol Biol (1971) 7.10
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell (1998) 5.89
A rapid method for detecting and mapping homology between heterologous DNAs. Evaluation of polyomavirus genomes. J Biol Chem (1979) 5.32
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
A map of simian virus 40 transcription sites expressed in productively infected cells. J Mol Biol (1973) 5.02
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A (1986) 4.43
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol (1996) 4.08
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol (1993) 3.90
Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins. J Virol (1986) 3.89
Nucleotide sequence and genome organization of foot-and-mouth disease virus. Nucleic Acids Res (1984) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Patterns of Simian Virus 40 DNA transcription after acute infection of permissive and nonpermissive cells. Proc Natl Acad Sci U S A (1972) 3.65
Genetic recombination of human immunodeficiency virus. J Virol (1989) 3.61
The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol (1996) 3.56
The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol (1989) 3.36
SV40 gene activity during lytic infection and in a series of SV40 transformed mouse cells. Proc Natl Acad Sci U S A (1969) 3.30
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A (2006) 3.26
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA (1991) 3.25
Identification of ecotropic proviral sequences in inbred mouse strains with a cloned subgenomic DNA fragment. Proc Natl Acad Sci U S A (1980) 3.19
Molecular cloning of polyoma virus DNA in Escherichia coli: lambda phage vector system. Science (1979) 3.17
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
Envelope and long terminal repeat sequences of a cloned infectious NZB xenotropic murine leukemia virus. J Virol (1985) 3.06
Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J Virol (1979) 3.04
Characterization of murine leukaemia virus-specific DNA present in normal mouse cells. Nat New Biol (1973) 2.98
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
A second protease of foot-and-mouth disease virus. J Virol (1986) 2.87
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol (1994) 2.83
The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem (1995) 2.70
Common methionine-tryptic peptides near the amino-terminal end of primate papovavirus tumor antigens. Proc Natl Acad Sci U S A (1978) 2.63
Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol (1993) 2.63
Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis (1997) 2.60
Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J Virol (1989) 2.60
Structure of the FMDV translation initiation site and of the structural proteins. Nucleic Acids Res (1983) 2.58
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med (1999) 2.53
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol (1995) 2.48
Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett (1996) 2.43
Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol (1995) 2.43
CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol (1998) 2.38
Nucleotide sequence of a full-length human endogenous retroviral segment. J Virol (1985) 2.36
Characterization of polyoma viral DNA sequences in polyoma-induced hamster tumor cell lines. J Biol Chem (1980) 2.33
Thermal stabilities and species specificities of reannealed animal deoxyribonucleic acids. Biochemistry (1966) 2.32
Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation. J Virol (1991) 2.30
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
Transcription of novel open reading frames of AIDS retrovirus during infection of lymphocytes. Science (1985) 2.28
Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol (1995) 2.27
Identification and cloning of endogenous retroviral sequences present in human DNA. Proc Natl Acad Sci U S A (1981) 2.26
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
Physical map of the BK virus genome. J Virol (1975) 2.18
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16
The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol (1996) 2.10
Endogenous murine leukemia proviral long terminal repeats contain a unique 190-base-pair insert. Proc Natl Acad Sci U S A (1983) 2.10
Cloning and characterization of an envelope-specific probe from xenotropic murine leukemia proviral DNA. J Virol (1982) 2.09
Specific hybridization probes demonstrate fewer xenotropic than mink cell focus-forming murine leukemia virus env-related sequences in DNAs from inbred laboratory mice. J Virol (1986) 2.08
Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing. Virology (1991) 2.05
Patterns of simian virus 40 deoxyribonucleic acid transcription. II. In transformed cells. J Virol (1973) 2.04
Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol (1998) 2.01
mRNA transcripts related to full-length endogenous retroviral DNA in human cells. Nature (1984) 1.94
The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif. J Mol Biol (1994) 1.93
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J Virol (1994) 1.92
Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol (1998) 1.90